| 282 | 6 | 60 |
| 下载次数 | 被引频次 | 阅读次数 |
目的研究口服小剂量甲氨蝶呤(MTX)的类风湿关节炎(RA)患者红细胞中多聚谷氨酸化甲氨蝶呤(MTXPGs)浓度与临床疗效及肝毒性之间的相关性。方法前瞻性收集医院128例接受小剂量MTX治疗的RA患者,观察其疗效和不良反应;采用LC-MS/MS法检测患者红细胞中MTXPGs浓度,使用SPSS软件分析MTXPGs浓度与疗效及肝毒性的相关性。结果94例(73.4%)患者治疗有效,34例(26.6%)患者治疗无效,其中16例(12.5%)患者发生肝毒性。Mann-Whitney U检验结果显示,有效组与无效组的MTXPGs浓度差异有统计学意义(U=1 320,P<0.01),发生肝毒性组与未发生肝毒性组MTXPGs浓度有统计学意义(U=544,P<0.05)。ROC分析显示,当ΔDAS28> 1.2时,MTXPGs浓度的临界值为25μg·L-1(P <0.001);当AST或ALT超过正常值上限时,MTXPGs浓度的临界值为38μg·L-1(P <0.05)。说明当浓度范围为25～38μg·L-1时,患者疗效好且肝毒性小。结论红细胞中MTXPGs浓度与RA患者临床疗效及肝毒性间存在相关性,临床药师有必要通过监测MTXPGs浓度来指导临床合理用药。
Abstract：AIM To study the correlation of methotrexate polyglutamates(MTXPGs) concentration in erythrocytes with clinical efficacy and hepatotoxicity in patients with rheumatoid arthritis(RA) orally taking low-dose methotrexate(MTX). METHODS Totally 128 RA patients receiving low dose MTX were prospectively collected to observe the efficacy and adverse reactions. The concentration of MTXPGs in erythrocytes was detected by LC-MS/MS, and the correlation between MTXPGs concentration and efficacy and hepatotoxicity was analyzed by SPSS software. RESULTS 94 patients(73.4%) were effective and 34(26.6%) were ineffective, and 16 patients(12.5%) developed hepatotoxicity.Mann-whitney U test results showed that the concentrations of MTXPGs in the effective group and the ineffective group were significantly different(U = 1 320, P < 0.01), and the concentrations of MTXPGs in the hepatotoxicity group and the non-hepatotoxicity group were significantly different(U = 544, P < 0.05). ROC analysis showed that when ?DAS28 > 1.2,the critical value of MTXPGs concentration was 25 μg·L-1(P < 0.001); and when AST or ALT exceeded the upper limit of normal value, the critical value of MTXPGs concentration was 38 μg·L-1(P < 0.05). The results indicated that when the concentration range was 25-38 μg·L-1, the patients had good effect and low hepatotoxicity. CONCLUSION There is a correlation between the concentration of MTXPGs in erythrocytes and the clinical efficacy and hepatotoxicity of RA patients, so it is necessary to monitor the concentration of MTXPGs to guide clinical rational drug use.
[1]SMOLEN J S,ALETAHA D,MCINNES I B.Rheumatoid arthritis[J].Lancet,2016,388(10055):2023.
[2]FAVALLI E G,BIGGIOGGERO M,MERONI P L.Methotrexate for the treatment of rheumatoid arthritis in the biologic era:still an"anchor"drug?[J].Autoimmun Rev,2014,13(11):1102.
[3]SALLIOT C,VAN DER HEIJDE D.Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis:a systematic literature research[J].Ann Rheum Dis,2009,68(7):1100.
[4]HIRAGA Y,YUHKI Y,ITOH K,et al.Pharmacokinetics and efficacy of low-dose methotrexate in patients with rheumatoid arthritis[J].Mod Rheumatol,2004,14(2):135.
[5]中国医师协会风湿免疫科医师分会.甲氨蝶呤在风湿性疾病中的应用中国专家共识[J].中华内科杂志,2018,57(10):719.
[6]DALRYMPLE J M,STAMP L K,O'DONNELL J L,et al.Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis[J].Arthritis Rheum,2008,58(11):3299.
[7]PAN S,STAMP L K,DUFFULL S B,et al.Assessment of the relationship between methotrexate polyglutamates in red blood cells and clinical response in patients commencing methotrexate for rheumatoid arthritis[J].Clin Pharmacokinet,2014,53(12):1161.
[8]SANDHU A,DHIR V,BHATNAGAR A,et al.High methotrexate triglutamate level is an independent predictor of adverse effects in Asian Indian rheumatoid arthritis patients-a preliminary study[J].Ther Drug Monit,2017,39(2):157.
[9]DE ROTTE M C,DEN BOER E,DE JONG P H,et al.Methotrexate polyglutamates in erythrocytes are associated with lower disease activity in patients with rheumatoid arthritis[J].Ann Rheum Dis,2015,74(2):408.
[10]彭颖，肖青青，束庆,等.多聚谷氨酸化甲氨蝶呤与类风湿关节炎疗效和不良反应的相关性研究进展[J].药学进展,2017,41(2):132.
[11]NEOGI T,ALETAHA D,SILMAN A J,et al.The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis:phase 2 methodological report[J].Arthritis Rheum,2010,62(9):2582.
[12]PORTER D,GADSBY K,THOMPSON P,e t a l.DAS28and rheumatoid arthritis:the need for standardization[J].Musculoskeletal Care,2011,9(4):222.
[13]杜思颖，吕佩瑜，温悦，等.HPLC-MS/MS间接测定类风湿关节炎患者红细胞中多聚谷氨酸化甲氨蝶呤的浓度[J].中国药学杂志,2019,54(22):1876.
[14]罗彦，王志中，王勇，等.多聚谷氨酸化甲氨蝶呤浓度与类风湿关节炎疗效相关性研究[J].第三军医大学学报,2011,33(5):473.
[15]MIAN A N,IBRAHIM F,SCOTT D L,et al.Optimal responses in disease activity scores to treatment in rheumatoid arthritis:is a DAS28reduction of>1.2 sufficient?[J].Arthritis Res Ther,2016,18(1):142.
[16]中华医学会肝病学分会药物性肝病学组.药物性肝损伤诊治指南[J].中华肝脏病杂志,2015,23(11):810.
[17]STAMP L K,O'DONNELL J L,CHAPMAN P T,et al.Determinants of red blood cell methotrexate polyglutamate concentrations in rheumatoid arthritis patients receiving long-term methotrexate treatment[J].Arthritis Rheum,2009,60(8):2248.
[18]冯健华.类风湿关节炎患者就医及治疗现状的分析[J].中国医药指南,2013,11(5):411.
[19]TAKAHASHI C,KANEKO Y,OKANO Y,et al.Association of erythrocyte methotrexate-polyglutamate levels with the efficacy and hepatotoxicity of methotrexate in patients with rheumatoid arthritis:a76-week prospective study[J].RMD Open,2017,3(1):e000363.
[20]DERVIEUX T,GREENSTEIN N,KREMER J.Pharmacogenomic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritis[J].Arthritis Rheum,2006,54(10):3095.
[21]莫小兰.相关基因多态性与甲氨蝶呤治疗风湿疾病疗效及不良反应的相关性研究[D].中山大学,2009.
基本信息:
DOI：10.19577/j.1007-4406.2022.01.002
中图分类号:R593.22
引用信息:
[1]杜思颖,温悦,吕佩瑜,等.多聚谷氨酸化甲氨蝶呤浓度与类风湿关节炎临床疗效及肝毒性之间的相关性[J].中国临床药学杂志,2022,31(01):5-10.DOI:10.19577/j.1007-4406.2022.01.002.
基金信息:
福建省科技计划项目资助（编号2018J01394）
2022-01-25
2022-01-25